Owner Scorecard


← All companies ← COR Manual CORZ → ← COLL Pharmaceuticals CPHI →

CORT, Corcept Therapeutics Incorporated

Pharmaceuticals consumer brand Cyclical

We are a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

Cortisol influences metabolism and the immune system and contributes to emotional stability.

Hypercortisolism can affect every organ system in the body and can be lethal if not treated.

Latest annual: FY2025 10-K
CORT · Corcept Therapeutics Incorporated
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$761M
+12.8% YoY · 17% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $831M 5-yr avg $537M
Operating margin 0.8% 5-yr avg 22.1%
ROIC 1% 5-yr avg 23%
Owner-earnings margin 13% 5-yr avg 30%
Free cash flow margin 13% 5-yr avg 30%

Next report Est. 10/26–11/5 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~31 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
What moves the needle
Gross margin has run about 98% and operating margin about 31% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from 5.9% to 36% — on a steadier 98% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. The cash cycle has run negative through the cycle (a median of −342 days): the operation is paid before it pays, so working capital releases cash as the business grows rather than tying it up. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has run high across the record (median 25%, above 15% in 8 of 9 years). Owner earnings agree: roughly 34% of revenue reaches owners as cash, consistently, and customers and suppliers fund the business through negative working capital. Whether these returns reflect real pricing power or an accounting artifact is the judgment the 10-K is for.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$81M$159M$251M$306M$354M$366M$402M$482M$675M$761M$831MRevenueRevenue
$79M$156M$246M$301M$348M$361M$396M$476M$664M$748M$817MGross profitGross prof.
97%98%98%98%98%99%99%99%98%98%98%Gross marginGross mgn
56%39%32%33%30%33%38%38%42%59%67%SG&A / revenueSG&A/rev
29%25%30%29%32%31%33%38%37%33%31%R&D / revenueR&D/rev
$10M$53M$89M$112M$128M$124M$113M$107M$137M$45M$6MOperating incomeOp. inc.
12.5%33.2%35.6%36.4%36.2%34.0%28.0%22.2%20.3%5.9%0.8%Operating marginOp. mgn
$8M$53M$92M$117M$132M$125M$116M$125M$161M$66MPretax incomePretax
$8M$129M$75M$94M$106M$113M$101M$106M$141M$100M$55MNet incomeNet inc.
0%18%19%19%10%13%15%13%Effective tax rateTax rate
Cash flow & returns
$18M$61M$116M$136M$152M$168M$120M$127M$198M$142M$110MOperating cash flowOp. cash
$87K$106K$236K$703K$525K$1M$1M$1M$795K$1M$2MDepreciation & amortizationD&A
$3M($82M)$16M$12M$12M$11M($25M)($29M)($5M)($43M)($43M)Working capital & otherWC & other
$194K$419K$298K$1M$1M$469K$413K$139K$2M$211K$3MCapexCapex
0.2%0.3%0.1%0.4%0.3%0.1%0.1%0.0%0.3%0.0%0.3%Capex / revenueCapex/rev
$18M$61M$115M$135M$151M$167M$120M$127M$198M$142M$108MOwner earningsOwner earn.
22.5%38.2%45.9%44.2%42.8%45.7%29.8%26.2%29.3%18.6%13.0%Owner earnings marginOE mgn
$18M$61M$115M$135M$151M$167M$120M$127M$196M$142M$107MFree cash flowFCF
22.4%38.0%45.9%44.1%42.6%45.7%29.8%26.2%29.1%18.6%12.9%Free cash flow marginFCF mgn
$0$0$24M$31M$10M$0$0$16M$173MBuybacksBuybacks
($194K)($73M)($91M)($118M)($119M)$136M($114M)$91M($178M)$70MInvesting cash flowInv. cash
($7M)($8M)($14M)($29M)$12M($303M)($17M)($149M)($28M)($220M)Financing cash flowFin. cash
$358K($228K)$1MExchange-rate effectFX
$11M($20M)$11M($10M)$45M$1M($11M)$69M($8M)($7M)Change in cashΔ cash
33%31%27%23%38%23%25%22%8%1%ROICROIC
20%68%27%25%20%30%20%21%21%15%8%Return on equityROE
20%68%27%25%20%30%20%21%21%15%8%Retained to equityRetained/eq
Balance sheet
$52M$104M$42M$31M$76M$78M$437M$425M$603M$532M$545MCash & investmentsCash+inv
$10M$15M$18M$20M$26M$28M$31M$41M$54M$60M$77MReceivablesReceiv.
$2M$5M$5M$5M$5M$5M$6M$8M$12M$13M$13MInventoryInvent.
$2M$9M$8M$8M$11M$7M$12M$17M$15M$40M$15MAccounts payablePayables
$10M$11M$14M$18M$21M$26M$25M$31M$51M$32M$75MOperating working capitalOper. WC
$66M$124M$237M$307M$479M$266M$499M$459M$472M$485M$440MCurrent assetsCur. assets
$27M$30M$36M$39M$47M$48M$72M$105M$141M$166M$154MCurrent liabilitiesCur. liab.
2.4×4.2×6.7×7.9×10.1×5.6×6.9×4.4×3.4×2.9×2.9×Current ratioCurr. ratio
$205K$518K$655K$1M$2M$1M$633K$195K$3M$2MNet PP&ENet PP&E
$69M$221M$312M$412M$572M$424M$583M$622M$841M$837M$889MTotal assetsAssets
$30M$36M$41M$48M$48M$82M$115M$161M$189MTotal liabilitiesTotal liab.
$41M$191M$276M$371M$523M$376M$502M$507M$680M$648M$706MShareholders’ equityEquity
8.7%8.4%9.5%9.6%9.5%11.7%10.6%10.1%9.1%11.1%11.6%Stock comp / revenueSBC/rev
Per share
116M125M127M123M124M126M116M112M113M120M116MShares out (diluted)Shares
$0.70$1.28$1.98$2.50$2.85$2.91$3.47$4.32$5.95$6.35$7.14Revenue / shareRev/sh
$0.07$1.04$0.60$0.77$0.85$0.89$0.87$0.95$1.24$0.83$0.47EPS (diluted)EPS
$0.16$0.49$0.91$1.10$1.22$1.33$1.03$1.13$1.74$1.18$0.93Owner earnings / shareOE/sh
$0.16$0.49$0.91$1.10$1.21$1.33$1.03$1.13$1.73$1.18$0.92Free cash flow / shareFCF/sh
$0.00$0.00$0.00$0.01$0.01$0.00$0.00$0.00$0.02$0.00$0.02Cap. spending / shareCapex/sh
$0.36$1.53$2.18$3.03$4.21$2.98$4.33$4.53$5.99$5.40$6.06Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+27.8%/yr+17.4%/yr
Owner earnings / share+25.1%/yr−0.6%/yr
EPS+31.6%/yr−0.5%/yr
Capital spending / share+0.6%/yr−29.3%/yr
Book value / share+35.3%/yr+5.1%/yr

Where the cash went

ReinvestBuybacksDividendsAcquisitionsRetained

Each year's operating cash, by what management did with it: the mix, and how it drifts.

FY2016FY2025

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business turned $100M of profit into $142M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

Reported net income$100M
Owner earnings$142M · 19% of revenue
FY2025FY2024FY2023FY2022FY2021
Reported net income$100M$141M$106M$101M$113M
Depreciation & amortizationnon-cash charge added back+$1M+$795K+$1M+$1M+$1M
Stock-based compensationreal costnon-cash, but a real cost+$85M+$61M+$49M+$42M+$43M
Working capital & othertiming of cash in and out, other non-cash items−$43M−$5M−$29M−$25M+$11M
Cash from operations$142M$198M$127M$120M$168M
Maintenance capital expenditurethe spending needed just to hold position and volume−$211K−$795K−$139K−$413K−$469K
Owner earnings$142M$198M$127M$120M$167M
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$1M
Free cash flow$142M$196M$127M$120M$167M
Owner-earnings marginowner earnings ÷ revenue19%29%26%30%46%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $85M), owner earnings is nearer $57M.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash, debt-free
    Cash $120M + ST investments $252M − debt $0
    What this means

    Cash and short-term investments exceed every dollar of debt by $372M, on net the company owes nothing, and can act from strength when others can't. It also holds $160M in longer-dated marketable securities; counting those, it sits at net cash of $532M. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Negative, funded by others
    DSO 29 + DIO 362 − DPO 1138 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. A negative cycle is a quiet moat: suppliers and customers fund the operation (Buffett's “float”), the company grows on other people's money.

Is it a good business?

  • High through the cycle
    9-yr median, range 8%–38%; 8% latest = NOPAT $45M ÷ invested capital $527M
    Industry peers: median 6%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 9 years (it ran 8% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High through the cycle
    10-yr median margin, range 19%–46%; latest $142M = operating cash $142M − maintenance capex $211K
    Industry peers: median 8%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 19% of revenue this year, a 34% median across 10 years. Treating stock comp as the real expense it is (less $85M of SBC) leaves $57M.

  • Cash-backed
    Cash from ops $142M ÷ net income $100M
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Returned more than it generated
    Dividends + buybacks $173M ÷ Owner Earnings $142M — this fiscal year
    What this means

    The company returned more than it generated: against $142M of Owner Earnings, $173M (122%) went back to shareholders, $0 dividends, $173M buybacks — the excess came from the balance sheet or borrowing, not the year's operations. Net of $85M stock comp, the real buyback was about $88M. Sustained, that pattern draws down cash or adds debt; the net-debt line above shows where it stands. This year's proportion is 122%; across the record (2016–2025) it is 21%, the capital-allocation section below.

  • Investing or harvesting? 0.18×
    Harvesting
    Capex $211K ÷ depreciation & amortization as filed $1M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 11.1%
    The count is rising
    Stock compensation $85M (fiscal 2025), 11.1% of revenue · repurchases $173M · diluted shares +3.5% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 4 of 5 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $761M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 2.92×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $0 vs $319M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Pass
    A profit every year (10-yr record) · no losses
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth Pass
    Earnings +33% over the record · +63%
    What this means

    At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $1.07/share (latest year $0.92), the averaged base the calculator's gate runs on, and book value is $5.99/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 10 of 10
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Operating margin 27% → 16% (3-yr avg ends)

    In the filing’s words The filing attributes gains to higher prices but names price competition too — and the margin slipped, so the pressure is winning here.

    What this means

    Through the cycle the operating margin slipped — about 27% early to 16% lately, median 28% — competition or costs are biting in.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Owner earnings growth +18%/yr
    What this means

    Owner earnings grew about 18% a year over the record.

  • Worst year 2025 · 5.9% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count +0.4%/yr
    What this means

    Roughly flat share count, little dilution, little buyback.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$440M
  • Cash & short-term investments$308M
  • Receivables$77M
  • Inventory$13M
  • Other current assets$41M
Current liabilities$154M
  • Accounts payable$15M
  • Other current liabilities$139M
Current ratio2.86×all current assets ÷ what's due · Graham looked for 2×
Quick ratio2.77×stricter: inventory excluded
Cash ratio2.00×strictest: cash alone against what's due
Working capital$286Mthe cushion left after near-term bills
Revenue, latest quarter vs. a year ago+31.7%the freshest read on whether the business is still growing
Current ratio, recent quarters3.7× → 2.9×
Deeper floors
Tangible book value$706Mequity stripped of goodwill & intangibles
Net current asset value$257MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$9M$9M of it operating leases

From the company's latest filing.

How the cash was used, 2016–2025

Over the record, the business generated $1.2B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested$7M · 1%
  • Buybacks$253M · 20%
  • Retained (debt / cash)$978M · 79%
  • Returned to owners$253M

    21% of the owner earnings the business produced over the span, $0 as dividends and $253M as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span cash and short-term investments rose $257M.

  • Average price paid for buybacks

    Buybacks ran $253M over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count0.2%

    The diluted count barely moved (116M to 116M): buybacks roughly offset the stock issued to staff.

  • Dividend record

    No dividend line was reported in the filing data over the span; the record here neither confirms nor rules out a payout.

  • Return on what it retained13%

    Of the earnings it kept rather than paid out ($721M over the span), annual owner earnings (first three years vs last three) grew $90M, so each retained $1 added about 0.13 of yearly owner earnings. Buffett's test, run on owner earnings instead of market value.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Dr. Belanoff$11.0M$4.3M$167M
2022Dr. Belanoff$7.4M$9.6M$120M
2023Dr. Belanoff$9.3M$15.8M$127M
2024Dr. Belanoff$9.9M$22.8M$198M
2025Dr. Belanoff$15.3M$14.8M$142M

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership20.7%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$85M

    The slice of the business handed to employees in shares in fiscal 2025, 11.1% of revenue, equal to 188.6% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
ASNDAscendis Pharma A/S Ordinary Share$839M76%3y-76.7%3y-172%-176%1y
TLXTelix Pharmaceuticals Limited$804M63%3.7%18%3%
COLLCollegium Pharmaceutical Inc.$781M56%7.2%44%4y32%
CORTCorcept Therapeutics Incorporated$761M98%30.6%25%34%
EBSEmergent BioSolutions Inc.$743M60%12.5%6%8%
PCRXPacira BioSciences$726M73%3.7%2%16%
SUPNSupernus Pharmaceuticals Inc.$719M90%20.0%11%26%
KNSAKiniksa Pharmaceuticals International, PLC$678M88%-9.3%-6%5%
Group median75%5.4%8%12%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Corcept Therapeutics Incorporated has delivered.

$

Through the cycle, Corcept Therapeutics Incorporated earns about $259M on its 34.0% median owner-earnings margin. This year’s 18.6% margin runs below that; the reported figure may understate a lean year. Normalize, below, values the price on that through-cycle figure rather than the latest year.

Base

The assumptions

9.0% = the 4.71% 10-year Treasury (Aug 18, 2026) + 4.29 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’21→’25+4%/yr
Owner-earnings growth · ’16→’25+18%/yr
Owner-earnings yield
P/E (3-yr earnings ’23–’25)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.71%, as of Aug 18, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Free cash flow $107M on 108M shares outstanding, per the 10-Q cover, as of 2026-07-22; net cash $308M. The if-converted diluted count is 116M, 8% above the shares outstanding: the dilution overhang (convertibles, options) a buyer inherits. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($3M) runs well above depreciation ($2M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $109M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Cite: Owner Scorecard, "Corcept Therapeutics Incorporated (CORT), the owner's record," https://ownerscorecard.com/c/CORT, data as of 2026-08-17.

Manual order: ← COR its page in the Manual CORZ →

Industry order: ← COLL the Pharmaceuticals chapter CPHI →